Highest-materiality recent filing
cbdMD extends warehouse lease through 2031, cuts footprint and annual rent by ~$450k
Third Amendment to Lease extends term 62 months to Nov 30, 2031 for 40,000 sq ft (down from 80,000).
cbdMD grants RSUs to directors and sets annual cash retainers
Each independent director and non-management employee director receives 1,572 RSUs vesting quarterly through March 31, 2027.
Reverse stock split from 1:2 to 1:10 approved, board to set ratio within one year.
cbdMD buys Bluebird Botanicals CBD e-commerce assets for 425k shares plus 525k earnout
Acquired substantially all assets of Gaia Botanicals d/b/a Bluebird Botanicals: brand, domain, trademarks, inventory.
cbdMD regains NYSE American compliance; BC indicator removed Dec 8, 2025
Received NYSE American letter Dec 5, 2025 confirming compliance with Sections 1003(a)(i) and (ii).
CEO/CFO T. Ronan Kennedy signs 3-year term; base salary of $340,000 per year.
cbdMD Q4 net sales up 3-5% YoY; FY net loss improves to ~$2M from $3.7M
Net sales for fiscal 2025 expected $19.1–19.3M vs $19.5M prior year.
cbdMD raises $1.7M gross via Series B Convertible Preferred, net $1.5M for working capital
Issued 1,700,000 shares of Series B Convertible Preferred to four institutional investors for $1.7M gross proceeds.
cbdMD board grants RSUs to directors, sets annual cash retainers
Each independent director and non-management employee director receives 1,572 RSUs.
cbdMD converts all Series A Preferred to common, effects 1-for-8 reverse stock split
All 5,000,000 outstanding 8% Series A Preferred shares automatically converted into 65,000,000 common shares on May 6, 2025.
cbdMD shareholders approve automatic conversion of Series A Preferred Stock into common at 13:1
Shareholders approved automatic conversion of each Series A Preferred share into 13 common shares, eliminating $6.7M in accrued dividends and $4M annual dividend obligations.
cbdMD fully converts remaining $56K senior secured notes to equity, now debt-free
Remaining $56,000 Senior Secured Convertible Notes converted to common stock on Jan 14, 2025.
cbdMD reduces convertible note debt to $56K; issued 609K shares; Q1 cash ~$2.1M
Convertible note principal reduced to ~$56,000 as holders converted ~$309,000 principal plus accrued interest.
cbdMD receives additional NYSE American noncompliance notice for equity under $2M
Stockholders' equity $1,963,417 as of Sep 30, 2024, below $2M threshold; losses in 4 of 5 recent fiscal years.
cbdMD appoints CEO/CFO Ronan Kennedy to Board, expanding to 5 members
Expanded Board from 4 to 5; Kennedy appointed effective Dec 18/19, 2024.
cbdMD extends warehouse lease through Sep 2026, discloses share issuance on debt conversion
Lease amended: 19-month extension from Mar 1, 2025 to Sep 30, 2026; monthly base rent $65K first year, $67.6K second year.
cbdMD gets NYSE American plan acceptance for listing; equity at $3.1M, deadline Dec 2025
NYSE American accepted cbdMD's plan to regain compliance; plan period through Dec 5, 2025.
cbdMD acquires 'CBD MD' trademark from Majik Medicine for cash/stock; settles litigation
Paid $100k cash on closing; will pay $50k annually for 4 years ($300k total) and issued 75k shares of common stock (50k more in year 2).
cbdMD receives NYSE American acceptance of compliance plan; faces Dec 5, 2025 deadline
Stockholders' deficit of $3.1M as of March 31, 2024; non-compliance with $4M equity requirement.
cbdMD settles former office lease, expects ~$780K in total gains
Paid $255K to satisfy all past due obligations under former lease; mutual release executed.
cbdMD settles former lease with $255K payment, records $550K gain
Made $255,000 payment on Aug 15, 2024 to satisfy all past due lease amounts; mutual release executed.
cbdMD reports 3,763,433 shares outstanding after note conversions; $1.08M notes balance
As of July 19, 2024, common shares outstanding: 3,763,433 after reconciling partial conversions of 8% Senior Secured Convertible Promissory Notes.
cbdMD submits NYSE American compliance plan; expects response in August 2024
Received NYSE American non-compliance notice on June 5, 2024 for continued listing standards.
Stockholders' equity was $3.1M as of March 31, 2024, below $4M minimum required by Section 1003(a)(ii).
Bradley Whitford appointed Chief Accounting Officer, Treasurer, Secretary; annual base salary $200,000.
cbdMD enters forbearance on sublease default, moves executive offices
Behind on rent since Sep 2023; default notice and summary ejectment filed Feb 2024.
cbdMD posts updated investor deck for non-deal roadshows; no material new info
Executives to use new investor presentation in non-deal roadshows starting Feb 29, 2024.
cbdMD raises $1.25M via convertible notes with 8% interest, automatic conversion price adjustments
Gross proceeds $1.25M; aggregate principal $1.54M due to original issue discount.
cbdMD cancels special meeting, withdraws Series A Preferred Stock conversion proposal
Special meeting scheduled for Oct 26, 2023 cancelled; proposal for automatic conversion of Series A Preferred Stock withdrawn.
cbdMD adjourns special meeting to Oct 26 to seek more votes on Series A conversion proposal
Special meeting adjourned from Sep 22 to Oct 26, 2023, 1:00 p.m. ET, due to insufficient votes.
cbdMD suspends Series A Preferred dividend, proposes mandatory conversion to common shares
Monthly cash dividend on 8% Series A Preferred suspended starting Aug 31, 2023 to conserve cash.
cbdMD declares $0.0667 monthly dividend on Series A Preferred Stock
Dividend of $0.0667 per share on 8.0% Series A Cumulative Convertible Preferred Stock.
cbdMD declares monthly dividend of $0.0667/share on Series A Preferred Stock
Dividend of $0.0667 per share on 8.0% Series A Cumulative Convertible Preferred Stock declared.
cbdMD begins using new investor deck in non-deal road shows
Executives will use an investor presentation (Exhibit 99.1) in non-deal road shows starting May 24, 2023.
cbdMD declares monthly dividend on 8.0% Series A Preferred Stock
Cash dividend of $0.0667 per share on 8.0% Series A Cumulative Convertible Preferred Stock.
cbdMD raises ~$2.5M net in underwritten public offering of 1.35M shares at $2.10
Issued 1,350,000 common shares at $2.10 each; gross proceeds ~$2.8M, net ~$2.5M.
cbdMD completes 1-for-45 reverse stock split effective April 24, 2023
Reverse split ratio of 1:45 effective 12:01 a.m. ET on April 24, 2023, as approved by shareholders on Feb 16, 2023.
cbdMD declares monthly $0.0667/share dividend on Series A Preferred
Dividend of $0.0667 per share on 8.0% Series A Cumulative Convertible Preferred Stock.
cbdMD approves 1-for-45 reverse stock split effective April 24, 2023
Reverse split reduces outstanding shares from ~65.5M to ~1.45M; fractional shares rounded up.
cbdMD declares monthly dividend of $0.0667 on Series A Preferred
Dividend of $0.0667 per share of 8.0% Series A Cumulative Convertible Preferred Stock.
cbdMD CEO resigns; enters equity line with Keystone for up to 12.7M shares
Kevin MacDermott resigned as Principal Executive Officer and President effective Feb 26, 2023; no disagreement cited.
cbdMD declares monthly cash dividend of $0.0667 per share on Series A Preferred Stock
Dividend of $0.0667 per share on 8.0% Series A Cumulative Convertible Preferred Stock.
Shareholders elected four directors: Bakari Sellers, William F. Raines III, Scott G. Stephen, Dr. Sibyl Swift; ratified Cherry Bekaert as auditor.
cbdMD to issue up to 6.06M shares for $2M advertising credit from a360 Media
Issues up to 6,060,606 shares at $0.33/share in exchange for a $2,000,000 advertising credit.
cbdMD declares $0.0667 monthly dividend on Series A Preferred Stock
Dividend of $0.0667/share on 8.0% Series A Cumulative Convertible Preferred Stock (YCBDpA).
cbdMD declares $0.0667 monthly dividend on Series A Preferred Stock payable Jan 17, 2022
Dividend of $0.0667 per share declared on 8.0% Series A Cumulative Convertible Preferred Stock.
cbdMD declares $0.0667 monthly dividend on Series A Preferred Stock
Dividend of $0.0667 per share on 8.0% Series A Cumulative Convertible Preferred Stock.
cbdMD declares monthly $0.0667 dividend on Series A Preferred, payable Nov 15
Monthly cash dividend of $0.0667 per share on 8.0% Series A Cumulative Convertible Preferred Stock declared.
cbdMD posts investor deck for non-deal road shows; no material news disclosed
cbdMD posted an investor presentation on Oct 3, 2022 for non-deal road shows.
cbdMD declares $0.0667 monthly dividend on 8.0% Series A Preferred, payable Oct 17
Monthly cash dividend of $0.0667 per share declared on 8.0% Series A Cumulative Convertible Preferred Stock.
Effective March 29, 2024, the Board of Directors (the "Board") of cbdMD, Inc. (the "Company") appointed Bradley Whitford, the Company's current Vice President of Finance, to serve as the Company's Chief Accounting Officer at the discretion of the Board.
On March 1, 2023, T. Ronan Kennedy agreed to serve as the Company’s Interim Chief Executive Officer and Principal Executive Officer and resigned as Chief Operating Officer of the Company in connection thereto.
On February 26, 2023, Kevin MacDermott notified cbdMD, Inc. (the “Company”) he was resigning as Principal Executive Officer and President of the Company, effective February26, 2023.
whereby he resigned as the Company’s Chief Executive Officer, member of the Board of Directors, employee, and all other capacities from the Company, effective June 11, 2022.
On June 11, 2022, Mr. Martin A. Sumichrast entered into a Separation Agreement (the “Separation Agreement”) with cbdMD, Inc. (the “Company”) and its subsidiaries whereby he resigned as the Company’s Chief Executive Officer, member of the Board of Directors, employee, and all other capacities from the Company, effective June 11, 2022.
On June 3, 2022 (the “Effective Date”) Scott G. Stephen, a member of the board of directors of cbdMD, Inc. (the “Company”) assumed the position of chairman of the board of directors of the Company as Martin A. Sumichrast agreed to vacate the position of chairman of the board of directors on the Effective Date.
Martin A. Sumichrast agreed to vacate the position of chairman of the board of directors on the Effective Date.
On the Effective Date, the Company entered into an Executive Employment Agreement with Kevin MacDermott pursuant to which Mr. MacDermott was hired to serve as the Company’s President.
On January 5, 2022 Sim Farar announced his resignation from our board of directors, effective immediately.
On December 1, 2021, John J. Wiesehan entered into a Separation and General Release (the “Separation Agreement”) with the cbdMD, Inc. (the “Company”) and its subsidiaries resigning as Chief Revenue Officer and all other capacities, effective December 1, 2021.
Mr. John J. Wiesehan III was appointed Chief Revenue Officer of the Company.
Max materiality 0.85 · Median 0.53 · Most common event other_material